The molecular mechanisms promoting this phenotype are still largely unknown, which hinders the development of an effective, specific therapies to treat or prevent metastatic disease, which is however a requirement for improving the prognosis for patients with EWS. The gene discussed is EWSR1; the disease is metastatic neoplasm.